TOKYO, Oct 21 (Reuters) - Japan' Shionogi & Co Ltd
said on Wednesday it had started a Phase II/III clinical trial
for its COVID-19 vaccine candidate.
The trial for the recombinant protein-based vaccine will
take place in Japan and follows a Phase I trial in the country,
Shionogi said in a statement. The company will also prepare to
conduct multiple trials globally, it said.
Medicines usually have to pass three phases of clinical
trials before they can be assessed for approval by regulators.
Separately, Daiichi Sankyo Co said it planned to
start a Phase II trial for its COVID-19 vaccine candidate next
The Japanese drugmaker is aiming for commercialization of
the mRNA-type vaccine, known as DS-5670, in 2022, it said in a
(Reporting by Rocky Swift Editing by Jacqueline Wong and Mark